Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

20
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
20
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

18
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
18
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

24
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
24
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

22
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
22
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

23
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
23
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

20
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
20

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Industry Practices in Monoclonal Antibody Tissue Biodistribution Assessment: An IQ Consortium Cross-Industry Survey of Current Approaches and Emerging Trends.

The AAPS journal·2026
Same author

Industry Practices in Oligonucleotide Tissue Biodistribution Assessment: An IQ consortium Cross-Industry Survey of Current Approaches and Emerging Trends.

The AAPS journal·2026
Same author

Collagen Fiber Orientation Regulates 3D Vascular Network Formation and Alignment.

ACS biomaterials science & engineering·2021
See all related articles

Related Experiment Video

Updated: Feb 19, 2026

An Allele-specific Gene Expression Assay to Test the Functional Basis of Genetic Associations
10:17

An Allele-specific Gene Expression Assay to Test the Functional Basis of Genetic Associations

Published on: November 3, 2010

23.4K

A functional ancestry-linked regulatory haplotype influences CYP2D6 expression.

Michael McCoy1

  • 1Drug Metabolism and Pharmacokinetics & Modeling, Takeda Development Center Americas, Incorporation, Cambridge, MA, USA. Michael.McCoy1@Takeda.com.

The Pharmacogenomics Journal
|February 17, 2026
PubMed
Summary

Genetic variants influencing drug metabolism by Cytochrome P450 (CYP) enzymes are crucial for personalized medicine. This study highlights ancestry-specific regulatory variants in CYP2D6, impacting drug response and necessitating updated pharmacogenetic testing.

More Related Videos

Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing ChIP-seq
09:52

Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing ChIP-seq

Published on: April 19, 2013

24.9K
A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging
09:37

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging

Published on: July 14, 2016

8.8K

Related Experiment Videos

Last Updated: Feb 19, 2026

An Allele-specific Gene Expression Assay to Test the Functional Basis of Genetic Associations
10:17

An Allele-specific Gene Expression Assay to Test the Functional Basis of Genetic Associations

Published on: November 3, 2010

23.4K
Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing ChIP-seq
09:52

Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing ChIP-seq

Published on: April 19, 2013

24.9K
A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging
09:37

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging

Published on: July 14, 2016

8.8K

Area of Science:

  • Pharmacogenomics
  • Molecular biology
  • Genetics

Background:

  • Cytochrome P450 (CYP) enzymes are critical for metabolizing the majority of pharmaceutical drugs.
  • Limited understanding exists regarding regulatory genetic variants that influence CYP-mediated drug metabolism across diverse populations.
  • Previous research has primarily focused on coding variants, neglecting the impact of regulatory variations.

Purpose of the Study:

  • To comprehensively analyze regulatory variation across 54 Cytochrome P450 (CYP) genes using expression quantitative trait loci (eQTL) data.
  • To identify specific CYP genes with significant regulatory variation and characterize their functional and population-specific implications.
  • To assess the need for incorporating ancestry-specific regulatory variants into pharmacogenetic testing strategies.

Main Methods:

  • Utilized the Genotype-Tissue Expression (GTEx) database to analyze eQTLs for 54 CYP genes.
  • Performed in silico functional analysis to predict the impact of identified variants on transcription factor binding and chromatin accessibility.
  • Investigated population stratification and linkage disequilibrium of key variants with known functional alleles.

Main Results:

  • CYP2D6 exhibited the most extensive regulatory variation, with 249 identified variants, including two high-effect variants in strong linkage disequilibrium.
  • In silico analysis indicated that one variant disrupts numerous transcription factor binding sites within an accessible chromatin region.
  • These high-frequency variants (45% in East Asians vs. 2.5% in Europeans) are strongly linked to the reduced-function CYP2D6*10 allele.

Conclusions:

  • Ancestry-specific regulatory variants significantly contribute to inter-individual variability in drug metabolism.
  • The identified regulatory variants in CYP2D6 have substantial population-specific frequencies and functional implications.
  • Pharmacogenetic testing strategies must be updated to include these ancestry-specific regulatory variants for improved drug efficacy and safety.